Porton Fine Chemicals Ltd - Asset Resilience Ratio

Latest as of September 2025: 6.85%

Porton Fine Chemicals Ltd (300363) has an Asset Resilience Ratio of 6.85% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Explore Porton Fine Chemicals Ltd (300363) long-term investment share to see how much of total assets are deployed in long-term investments.

Liquid Assets

CN¥588.05 Million
≈ $86.05 Million USD Cash + Short-term Investments

Total Assets

CN¥8.58 Billion
≈ $1.26 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2020)

This chart shows how Porton Fine Chemicals Ltd's Asset Resilience Ratio has changed over time. See 300363 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets Composition Over Time

This chart breaks down Porton Fine Chemicals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Porton Fine Chemicals Ltd's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥588.05 Million 6.85%
Total Liquid Assets CN¥588.05 Million 6.85%

Asset Resilience Insights

  • Limited Liquidity: Porton Fine Chemicals Ltd maintains only 6.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Porton Fine Chemicals Ltd Industry Peers by Asset Resilience Ratio

Compare Porton Fine Chemicals Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Krka d. d
WAR:KRK
Drug Manufacturers - Specialty & Generic 11.18%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
Drug Manufacturers - Specialty & Generic 4.97%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263
Drug Manufacturers - Specialty & Generic 6.08%
Tianjin Ringpu Bio Tech
SHE:300119
Drug Manufacturers - Specialty & Generic 14.27%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Porton Fine Chemicals Ltd (2017–2020)

The table below shows the annual Asset Resilience Ratio data for Porton Fine Chemicals Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 0.09% CN¥4.14 Million
≈ $605.43K
CN¥4.50 Billion
≈ $658.04 Million
+0.09pp
2019-12-31 0.01% CN¥224.20K
≈ $32.81K
CN¥3.96 Billion
≈ $578.81 Million
-13.03pp
2018-12-31 13.03% CN¥570.21 Million
≈ $83.44 Million
CN¥4.37 Billion
≈ $640.12 Million
+13.00pp
2017-12-31 0.04% CN¥1.06 Million
≈ $155.70K
CN¥2.85 Billion
≈ $416.76 Million
--
pp = percentage points

About Porton Fine Chemicals Ltd

SHE:300363 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.72 Billion
CN¥11.77 Billion CNY
Market Cap Rank
#6710 Global
#1391 in China
Share Price
CN¥21.65
Change (1 day)
+5.92%
52-Week Range
CN¥13.32 - CN¥29.41
All Time High
CN¥97.10
About

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more